1. Home
  2. KINS vs GNFT Comparison

KINS vs GNFT Comparison

Compare KINS & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KINS
  • GNFT
  • Stock Information
  • Founded
  • KINS 1886
  • GNFT 1999
  • Country
  • KINS United States
  • GNFT France
  • Employees
  • KINS N/A
  • GNFT N/A
  • Industry
  • KINS Property-Casualty Insurers
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KINS Finance
  • GNFT Health Care
  • Exchange
  • KINS Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • KINS 215.4M
  • GNFT 186.3M
  • IPO Year
  • KINS N/A
  • GNFT 2019
  • Fundamental
  • Price
  • KINS $13.98
  • GNFT $3.99
  • Analyst Decision
  • KINS
  • GNFT Strong Buy
  • Analyst Count
  • KINS 0
  • GNFT 1
  • Target Price
  • KINS N/A
  • GNFT $13.00
  • AVG Volume (30 Days)
  • KINS 249.6K
  • GNFT 4.0K
  • Earning Date
  • KINS 08-07-2025
  • GNFT 09-18-2025
  • Dividend Yield
  • KINS 0.36%
  • GNFT N/A
  • EPS Growth
  • KINS 325.10
  • GNFT N/A
  • EPS
  • KINS 2.04
  • GNFT 0.03
  • Revenue
  • KINS $183,702,376.00
  • GNFT $73,187,701.00
  • Revenue This Year
  • KINS $41.35
  • GNFT $5.15
  • Revenue Next Year
  • KINS $12.33
  • GNFT N/A
  • P/E Ratio
  • KINS $6.86
  • GNFT $133.57
  • Revenue Growth
  • KINS 29.74
  • GNFT 105.01
  • 52 Week Low
  • KINS $8.11
  • GNFT $2.55
  • 52 Week High
  • KINS $22.40
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • KINS 37.93
  • GNFT 53.56
  • Support Level
  • KINS $15.03
  • GNFT $3.71
  • Resistance Level
  • KINS $16.16
  • GNFT $4.20
  • Average True Range (ATR)
  • KINS 0.83
  • GNFT 0.16
  • MACD
  • KINS -0.15
  • GNFT 0.02
  • Stochastic Oscillator
  • KINS 0.91
  • GNFT 60.23

About KINS Kingstone Companies Inc.

Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: